Antisense Therapeutics Limited
Description Antisense Therapeutics Limited, a pharmaceutical drug discovery and development company, creates, develops, and commercializes novel antisense therapeutics in Australia. The companys product pipeline comprises ATL1103, a Phase I clinical stage antisense drug to block growth hormone receptor expression and reduce the levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action, including acromegaly, diabetic retinopathy, diabetic nephropathy, and cancer. Its product pipeline also includes ATL1101, a preclinical research stage antisense inhibitor of insulin like growth factor 1 receptor for the treatment of prostate cancer; and ATL1102, a Phase II antisense inhibitor to treat multiple sclerosis, and a preclinical research stage product for asthma. The company has strategic alliance with Tianjin Joint Academy of Biotechnology and Medicine or the development of ATL1102, as well as with Isis Pharmaceuticals, Inc. Antisense Therapeutics Limited is based in Toorak, Australia. To view the detailed information, you need to SUBSCRIBE with us. |
 |